XZXiangyu Zhou

Xiangyu Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiangyu Zhou has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • Yuan Zhang

    8 shared publications
  • Weijia Zeng

    Obstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China

    6 shared publications
  • Zhouping Lu

    Obstetrics and Gynecology Hospital of Fudan University Shanghai Key Lab of Reproduction and Development Shanghai Key Lab of Female Reproductive Endocrine Related Diseases Shanghai China

    5 shared publications
  • Jian-Yuan Zhao

    Institute for Developmental and Regenerative Cardiovascular Medicine, MOE-Shanghai Key Laboratory of Children’s Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200092

    4 shared publications
  • Weicheng Chen

    Pediatric Cardiovascular Center, Children’s Hospital of Fudan University, Shanghai, China

    4 shared publications
  • Yan Chen

    4 shared publications

Latest Publications

  • Open Access

    Acox2 deficiency induces cardiac dysfunction via cross-organ metabolic reprogramming in mice

    by Cancan Yao, Yan Chen, Zhouping Lu, Ke Cai, Feifei Wang, Boxuan Wu, Muling Zeng, Eudald Casals, Yuan Zhang, Xiangyu Zhou

    Background: Secondary cardiomyopathies are a major cause of heart failure (HF) with diverse etiologies and high mortality rates. For example, over 50% of patients with end-stage liver disease develop cardiac dysfunction, clinically termed cirrhotic cardiomyopathy (CCM). While serum metabolites mediating cross-organ communication are known to play a critical role in CCM development, the underlying pathogenic mechanisms remain poorly understood due to a lack of optimal experimental models. Methods: We generated Acox2 knockout (KO) mice using CRISPR/Cas9 technology to investigate the role of ACOX2, a rate-limiting peroxisomal enzyme. Cardiac function was assessed via echocardiography. We performed RNA sequencing and quantitative proteomic analyses to evaluate cardiac gene expression. Furthermore, global succinylome profiling was conducted to determine changes in protein succinylation, and global metabolomics analysis was used to identify significantly differentially expressed metabolites (SDMs). Results: Acox2 KO mice successfully recapitulated the hepatic phenotypes observed in patients with ACOX2 homozygous mutations, including liver fibrosis and lymphocytic infiltration. Given that ACOX2 is not expressed in the mouse heart throughout its lifespan, we initially hypothesized that Acox2 deficiency would have no direct impact on cardiac function. However, by 6 months of age, Acox2 KO mice exhibited significantly compromised cardiac parameters via echocardiography, alongside elevated biomarkers of cardiomyopathy and heart failure. While Acox2 deficiency had limited impact on the cardiac proteome, global succinylome profiling revealed a pervasive decrease in protein succinylation in Acox2 KO hearts. Notably, approximately 60% of these hypo-succinylated sites were located on mitochondrial and myofibrillar proteins, including SUCLA2 (K94), CS (K321), FH (K470), MDH1 (K110), OGDH (K999), TNNC1 (K86), VCL (K453), MYH7 (K83), and MYL3 (K9)—a profile tightly associated with cardiomyopathy. Seahorse assays and scanning electron microscopy further indicated impaired mitochondrial function in Acox2 KO mice. Metabolomic analysis revealed a dramatic accumulation of plasma C27 bile acid intermediates and a concomitant decrease in cardiac succinyl-CoA levels. Conclusions: Our findings underscore the critical role of the succinylation landscape in maintaining cardiac function. The cardiac pathology observed in Acox2 KO mice originates from cross-organ metabolic signaling, providing new insights into the pathogenesis of secondary cardiomyopathies, such as cirrhotic cardiomyopathy.

  • Open Access

    G3BP1 Succinylation at K413 is Critical for Cardiac Function by Modulating PI3K‐AKT‐mTOR Signal Axis

    by Yuan Zhang, Cancan Yao, Yan Chen, Ke Cai, Zhouping Lu, Boxuan Wu, Kun Yu, Yan Shi, Jianyuan Zhao, Xiangyu Zhou

    G3BP1, GTPase activating protein (SH3 domain) binding protein 1, is a core component of stress granules. Homozygous null mutations in the G3bp1 gene result in embryonic lethality, underscoring its essential role in development. While various post‐translational modifications regulate G3BP1 activity, here we first report that G3BP1 undergoes succinylation (Suc) at Lys (K)411 in mouse hearts (corresponding to human K413). G3BP1‐Suc level was diminished in Myosin binding protein C3 (Mybpc3) knockout and transverse aortic constriction (TAC) operated mice, which developed heart failure (HF). Site‐directed mutagenesis confirmed that the K413R mutation compromised the overall Suc level of G3BP1 in vitro. Mice injected with AAV9‐G3BP1 (WT) developed typical phenotypes of dilated cardiomyopathy (DCM) and HF when compared to mice injected with AAV9‐Ctrl and ‐G3BP1 (K411R) mice, suggesting a possible loss of functional effect of de‐Suc at K411. Moreover, Homozygous knock‐in G3bp1 (K411R) mice exhibited compromised cardiac parameters compared to WT littermates. De novo G3BP1 mutation (p.E411G) from a DCM patient disrupts Suc at K413. Mechanistically, G3BP1 de‐Suc at K413 induced Rraga expression and impaired TSC1/2 and IDE binding, ultimately leading to excessive activation of the PI3K‐AKT‐mTOR signaling axis. We demonstrate a critical role for G3BP1 Suc at K413 in cardiac function by modulating the PI3K‐AKT‐mTOR pathway, providing new insights into the non‐canonical function of G3BP1 in cardiomyopathy and HF pathogenesis.


  • Open Access

    Increased PRSS56 expression is a causal factor and therapeutic target for human axial high myopia

    by Boxuan Wu, Weijia Zeng, Kefu Tang, Jiawei Xiong, Xiaofen Mo, Qing Fu, Dan Fu, Renyuan Chu, Guoli Zhao, Lei Lu, et al.

    High myopia (HM), characterized by significant ocular axial length elongation, affects hundreds of millions of people and is often inherited, particularly in cases that develop during childhood or adolescence. Although numerous myopia loci (MYP) have been identified, most causative genes remain undefined. Here, we analyzed two large HM pedigrees and refined the critical region through haplotype linkage analysis to a 3.9-Mb interval on 2q37.1, which was previously reported as MYP12 with an unknown pathogenic gene. Whole-genome sequencing identified the noncoding promoter variants c.-187G>T and c.-187G>C in PRSS56 , encoding a trypsin-like serine protease, which exclusively co-segregated with all affected members in both pedigrees. Compared with matched controls, increased PRSS56 expression was observed in both patient-derived iPSCs carrying c.-187G>T and knock-in mice (c.-155G>T, corresponding to human c.-187G>T) that faithfully recapitulate myopia phenotypes. Noncoding PRSS56 variants promote self-expression via enhanced binding to the transcription factor EGR1, as confirmed by dual-luciferase assays. Notably, we demonstrated that higher PRSS56 levels directly increase ocular axial length in a dose- and activity-dependent manner in multiple transgenic mouse models. Guinea pig myopia models consistently exhibited high Prss56 expression, and short-wave light exposure reduced Prss56 mRNA levels and attenuated further axial elongation. Mechanistically, higher PRSS56 expression was associated with reduced abundance of myosin-4 in the sclera and with molecular signatures of scleral remodeling, which were in turn correlated with axial elongation. In conclusion, our findings provide strong genetic and functional evidence for the pathogenic role of noncoding PRSS56 variants in HM and highlight PRSS56 as a promising therapeutic target for juvenile HM.


  • Open Access

    ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma

    by Shiqi Ye, Wenhao Xu, Zheqi Chen, Chuanying Zhu, Qintao Ge, Jiahe Lu, Kun Chang, Xi Tian, Aihetaimujiang Anwaier, Shuxuan Zhu, et al.

    The rapid development of ICI-based immunotherapy has ushered in a promising era for clear cell renal cell carcinoma (ccRCC). However, durable clinical responses remain limited to a subset of patients. Therefore, identifying novel predictive biomarkers and developing effective combination immunotherapies are critical for advancing personalized ccRCC management. In this study, we report that ccRCC patients exhibiting elevated ACOX2 expression may benefit from PARPi in combination with ICI. Multi-omics cohorts show ACOX2 is significantly downregulated in ccRCC and correlated with improved clinical prognosis. ACOX2 inhibits the growth of ccRCC both in vitro and in vivo. Mechanistically, ACOX2 interacts with MRE11 and inhibits the binding of MRE11 and RAD50, thereby destabilizing the MRE11-RAD50-NBS1 (MRN) complex. Furthermore, ACOX2 activates the cGAS-STING pathway, correlates with more mature tertiary lymphoid structures (TLS), and enhances CD8+ T cell infiltration and activity. Therapeutically, preclinical ccRCC models with high ACOX2 expression, including ccRCC cells, cell-derived xenograft (CDX), patient-derived organoid (PDO), patient-derived xenograft (PDX), and immunocompetent mouse models show increased sensitivity to PARPi plus anti-PD-1 therapy. In conclusion, our findings elucidate a pivotal role of ACOX2 in inhibiting HRR and propose that PARPi, either alone or in combination with anti-PD-1 therapy, represents a promising treatment strategy for ccRCC with elevated ACOX2 expression.


  • Open Access

    De novo and inherited micro-CNV at 16p13.11 in 21 Chinese patients with defective cardiac left-right patterning

    by Kun Yu, Weicheng Chen, Yan Chen, Libing Shen, Boxuan Wu, Yuan Zhang, Xiangyu Zhou

    Objective: Copy number changes at Chromosomal 16p13.11 have been implicated in a variety of human diseases including congenital cardiac abnormalities. The clinical correlation of copy number variants (CNVs) in this region with developmental abnormalities remains controversial as most of the patients inherit the duplication from an unaffected parent.Methods: We performed CNV analysis on 164 patients with defective left-right (LR) patterning based on whole genome-exome sequencing (WG-ES) followed by multiplex ligation-dependent probe amplification (MLPA) validation. Most cases were accompanied with complex congenital heart disease (CHD).Results: CNVs at 16p13.11 were identified in a total of 21 cases, accounting for 12.80% (21/164) evaluated cases. We observed a marked overrepresentation of chromosome 16p13.11 duplications in cases when compared with healthy controls according to literature reports (15/164, 9.14% versus 0.09% in controls). Notably, in two independent family trios, de novo 16p13.11 micro-duplications were identified in two patients with laterality defects and CHD. Moreover, 16p13.11 micro-duplication was segregated with the disease in a family trio containing 2 affected individuals. Notably, five coding genes, NOMO1, PKD1P3, NPIPA1, PDXDC1, and NTAN1, were potentially affected by micro-CNV at 16p13.11 in these patients.Conclusion: Our study provides new family-trio based evidences to support 16p13.11 micro-duplications predispose individuals to defective cardiac left-right patterning and laterality disorder.


  • Versatile Antibacterial and Antioxidant Bacterial Cellulose@Nanoceria Biotextile: Application in Reusable Antimicrobial Face Masks

    by Jie Tang, Yuping Zhang, Xingfei Liu, Yichao Lin, Lihua Liang, Xiaofang Li, Gregori Casals, Xiangyu Zhou, Eudald Casals, Muling Zeng

    Despite considerable interest in medical and pharmaceutical fields, there remains a notable absence of functional textiles that concurrently exhibit antibacterial and antioxidant properties. Herein, a new composite fabric constructed using nanostructured bacterial cellulose (BC) covalently‐linked with cerium oxide nanoparticles (BC@CeO2NPs) is introduced. The synthesis of CeO2NPs on the BC is performed via a microwave‐assisted, in situ chemical deposition technique, resulting in the formation of mixed valence Ce3+/Ce4+ CeO2NPs. This approach ensures the durability of the composite fabric subjected to multiple washing cycles. The Reactive oxygen species (ROS) scavenging activity of CeO2NPs and their rapid and efficient eradication of >99% model microbes, such as Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus remain unaltered in the composite. To demonstrate the feasibility of incorporating the fabric in marketable products, antimicrobial face masks are fabricated with filter layers made of BC@CeO2NPs cross‐linked with propylene or cotton fibers. These masks exhibit complete inhibition of bacterial growth in the three bacterial strains, improved breathability compared to respirator masks and enhanced filtration efficiency compared to single‐use surgical face masks. This study provides valuable insights into the development of functional BC@CeO2NPs biotextiles in which design can be extended to the fabrication of medical dressings and cosmetic products with combined antibiotic, antioxidant and anti‐inflammatory activities.


  • Open Access

    Non-classical functions of nuclear pore proteins in ciliopathy

    by Yan Chen, Yuan Zhang, Xiangyu Zhou

    Nucleoporins (NUPs) constitute integral nuclear pore protein (NPC) elements. Although traditional NUP functions have been extensively researched, evidence of additional vital non-NPC roles, referred to herein as non-classical NUP functions, is also emerging. Several NUPs localise at the ciliary base. Indeed, Nup188, Nup93 or Nup205 knockdown results in cilia loss, impacting cardiac left–right patterning in models and cell lines. Genetic variants of Nup205 and Nup188 have been identified in patients with congenital heart disease and situs inversus totalis or heterotaxy, a prevalent human ciliopathy. These findings link non-classical NUP functions to human diseases. This mini-review summarises pivotal NUP interactions with NIMA-related kinases or nephronophthisis proteins that regulate ciliary function and explores other NUPs potentially implicated in cilia-related disorders. Overall, elucidating the non-classical roles of NUPs will enhance comprehension of ciliopathy aetiology.


  • Conservation of the enzyme-like activity and biocompatibility of CeO2 nanozymes in simulated body fluids

    by Muling Zeng, Xu Zhang, Jie Tang, Xingfei Liu, Yichao Lin, Dongdong Guo, Yuping Zhang, Shijie Ju, Guillermo Fernández-Varo, Ya-Chao Wang, et al.

    CeO2 nanozymes dispersed for 7 days in simulated body fluids maintain excellent biocompatibility and antioxidant properties. This work provides an experimental basis to explain their in vivo therapeutic effectiveness against chronic inflammation.


  • Open Access

    Gestational palmitic acid suppresses embryonic GATA-binding protein 4 signaling and causes congenital heart disease

    by Rui Zhao, Li Cao, Wen-Jun Gu, Lei Li, Zhong-Zhong Chen, Jie Xiang, Ze-Yu Zhou, Bo Xu, Wei-Dong Zang, Xiang-Yu Zhou, et al.